Recent advances in the development of immunoadhesins for immune therapy and as anti-infective agents.
Recombinant fusion proteins consisting of the extracellular domain of immunoregulatory proteins and the constant (Fc) domain of immunoglobulin (Ig) represent a growing class of human therapeutics. Immunoadhesins combine the binding region of a protein sequence, with a desired specificity, with the effector domain of an antibody. Immunoadhesins have two important properties that are significant to their potential as therapeutic agents: the target specificity, and the pharmacokinetic stability (half-life in vivo that is comparable to that of antibodies). Immunoadhesins can be used as antagonist to inhibit or block deleterious interactions or as agonist to mimic or enhance physiological responses. Here, we review the recent advances in the development of immunoadhesins as tools for immune therapy, particularly for the treatment of infectious diseases. The present article is a short review for the recent patents related to immunoadhesins for immune therapy.
Pérez de la Lastra
José M
JM
Instituto de Investigación en Recursos Cinegéticos, IREC (UCLM-CSIC-JCCLM), Ronda Toledo s/n, 13071 Ciudad Real, Spain. josemanuel.plastra@uclm.es
Kremer
Leonor
L
de la Fuente
José
J
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019138:Antibodies, Blocking / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000276:immunology* / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
D000890:Anti-Infective Agents; D019138:Antibodies, Blocking; D015815:Cell Adhesion Molecules